- Trials with a EudraCT protocol (355)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
355 result(s) found for: Vascular Surgery.
Displaying page 1 of 18.
EudraCT Number: 2007-005056-16 | Sponsor Protocol Number: ATORV/IMAPERIPROC | Start Date*: 2007-10-19 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: Atorvastatin at high dosage before coronary stent surgery: effect on peri-procedure miocardic stroke . | |||||||||||||
Medical condition: elective PCI in de novo coronaric lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004583-22 | Sponsor Protocol Number: 548.12 | Start Date*: 2012-10-20 | |||||||||||
Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA | |||||||||||||
Full Title: Verification of the effectiveness of intravenous sildenafil compared to other pulmonary vasodilators used in the test vessel reactivity of pulmonary | |||||||||||||
Medical condition: Subjects in children with congenital heart disease surgery or not, with echocardiographic signs of pulmonary hypertension followed at the Pediatric Cardiology Centre of the Mediterranean or reporte... | |||||||||||||
|
|||||||||||||
Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002157-38 | Sponsor Protocol Number: 57911 | Start Date*: 2017-09-14 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
Full Title: Treatment of congenital vascular malformations using Sirolimus: improving quality of Life | ||||||||||||||||||||||||||||
Medical condition: congenital vascular malformation : Vascular malformations can involve lymphatic vessels, capillaries, veins and arteries or even combinations. These vascular malformations are present at birth an... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001635-21 | Sponsor Protocol Number: VIA-2291-02 | Start Date*: 2006-12-21 | |||||||||||
Sponsor Name:VIA PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Phase 2 Randomised, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients wi... | |||||||||||||
Medical condition: Carotid Stenosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004116-32 | Sponsor Protocol Number: Protocol WIL1-0609 | Start Date*: 2008-12-03 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: EFFICACY AND SAFETY STUDY OF WILFACTIN ADMINISTERED BY CONTINUOUS INFUSION IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING MAJOR SURGICAL PROCEDURES | |||||||||||||
Medical condition: Severe von Willebrand disease patients undergoing elective major surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001584-36 | Sponsor Protocol Number: 2014-03-11 | Start Date*: 2016-06-01 |
Sponsor Name:Universitetssjukhuset Örebro | ||
Full Title: Is high oxygen concentration a riskfactor for postoperative complications? A prospective, randomized, singel blinded study in elderly patients undergoing vascular surgery | ||
Medical condition: Elective vascular surgery (peripheral vascular and aortic surgery) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005401-20 | Sponsor Protocol Number: CSLCT-BIO-03-97 | Start Date*: 2015-01-30 | |||||||||||
Sponsor Name:CSL Limited | |||||||||||||
Full Title: An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD) | |||||||||||||
Medical condition: Von Willebrand's disease (VWD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003884-37 | Sponsor Protocol Number: RONIN-CCV | Start Date*: 2023-05-26 |
Sponsor Name:Fernando Suarez Sipmann | ||
Full Title: Role of inhaled nitric oxide on right ventricular function and pulmonary vascular mechanics following cardiac surgery | ||
Medical condition: Patients in the immediate cardiac surgery post-operative period | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000664-85 | Sponsor Protocol Number: 8VWF03 | Start Date*: 2006-12-19 |
Sponsor Name:Bio Products Laboratory | ||
Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di... | ||
Medical condition: von Willebrand disease | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001426-84 | Sponsor Protocol Number: WIL-14 | Start Date*: 2006-02-09 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASE | |||||||||||||
Medical condition: Inherited von Willebrand Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005612-41 | Sponsor Protocol Number: 15-15 | Start Date*: 2015-11-30 | |||||||||||||||||||||||||||||||
Sponsor Name:Meander Medical Centre | |||||||||||||||||||||||||||||||||
Full Title: Vitamin c to Improve Tissue healing by Administration of Multiple INtravenous dosages | |||||||||||||||||||||||||||||||||
Medical condition: Patients with planned revascularisation surgery on the lower extremities. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003450-92 | Sponsor Protocol Number: IG1005 | Start Date*: 2013-11-23 | |||||||||||||||||||||
Sponsor Name:Instituto Grifols S.A. | |||||||||||||||||||||||
Full Title: EVALUATION OF THE PHARMACOKINETIC PROFILE, CLINICAL EFFICACY AND SAFETY OF THE VON WILLEBRAND FACTOR CONTAINED IN FANHDI® (DOUBLE-INACTIVATED HUMAN ANTI-HEMOPHILIC FACTOR) IN PEDIATRIC PATIENTS WIT... | |||||||||||||||||||||||
Medical condition: Severe von Willebrand disease including types I, II, and III with VWF:RCof <15-20% | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005051-34 | Sponsor Protocol Number: 42-73-305 / WIL1-0305 | Start Date*: 2005-04-18 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age | |||||||||||||
Medical condition: Von Willebrand disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000686-23 | Sponsor Protocol Number: RAVE_v1 | Start Date*: 2017-03-29 |
Sponsor Name:Erasmus MC | ||
Full Title: The Rotterdam Antiplatelet Therapy in Vascular Patients Study | ||
Medical condition: myocardial injury in patients undergoing major vascular surgery, leading to (spontaneous) acute coronary syndrome and death through intracoronary plaque damage and subsequent thrombosis after major... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003383-12 | Sponsor Protocol Number: CLN-PRO-V005 | Start Date*: 2021-07-05 | ||||||||||||||||
Sponsor Name:Humacyte, Inc. | ||||||||||||||||||
Full Title: A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte’s Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma | ||||||||||||||||||
Medical condition: Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001156-37 | Sponsor Protocol Number: CTSUSHARP1 | Start Date*: 2005-09-12 |
Sponsor Name:University of Oxford | ||
Full Title: Study of Heart and Renal Protection | ||
Medical condition: Chronic Kidney Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003575-38 | Sponsor Protocol Number: 071101 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE | |||||||||||||
Medical condition: Hereditary severe von Willebrand Disease in adult patients who will undergo major and minor elective surgical procedures | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GB (Completed) NL (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004868-69 | Sponsor Protocol Number: AP7000_1-4002 | Start Date*: 2005-03-07 | |||||||||||
Sponsor Name:ZLB Behring LLC | |||||||||||||
Full Title: Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease | |||||||||||||
Medical condition: Von Willebrand’s disease (VWD) is a common hereditary bleeding disorder. The impaired formation and adhesion of the initial platelet plug is reflected in the prolonged skin bleeding time. In addit... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005127-16 | Sponsor Protocol Number: IG1101 | Start Date*: 2014-06-16 |
Sponsor Name:Instituto Grifols, S.A. | ||
Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis during Peripheral Vascular Surgery | ||
Medical condition: Treatment of haemorrhage resulting from a vascular surgical procedure | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000022-75 | Sponsor Protocol Number: CV131-169 | Start Date*: 2004-09-24 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk | ||
Medical condition: Albuminuria in hypertensive subjects at increased cardiovascular risk. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) LV (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.